SCHEMBL1711265

SCHEMBL1711265

CC(=O)Oc1ccccc1C=CC(=O)O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.63
GAA P10253 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.57
KDM4E B2RXH2 4/20 0.56
PTGER1 P34995 1/20 0.55
PTGER4 P35408 1/20 0.55
PTGER3 P43115 1/20 0.55
PTGER2 P43116 1/20 0.55
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
NFKB1 P19838 1/20 0.53
CA4 P22748 1/20 0.53
NFE2L2 Q16236 2/20 0.53
TFEB P19484 1/20 0.53
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
HSP90AA1 P07900 1/20 0.52
TDP1 Q9NUW8 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1711263 1.00 HTT (0.63) HTTGAASMN1; SMN2KDM4EPTGER1
SCHEMBL4715093 1.00 HTT (0.63) HTTGAASMN1; SMN2KDM4EPTGER1
SCHEMBL13036867 0.88 NFE2L2 (0.69) HTTKDM4EMEN1KMT2ANFKB1
SCHEMBL20110943 0.88 KDM4E (0.72) HTTKDM4EMEN1KMT2ANFE2L2
SCHEMBL1603612 0.87 MEN1 (0.60) SMN1; SMN2KDM4EMEN1KMT2ANFKB1
SCHEMBL16498326 0.85 MAPT (0.72) HTTSMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL16498329 0.85 MAPT (0.72) HTTSMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL17305571 0.85 KDM4E (0.54) HTTGAAKDM4EMEN1KMT2A
SCHEMBL4712845 0.85 KDM4E (0.54) HTTGAASMN1; SMN2KDM4EMEN1
SCHEMBL18121457 0.85 KDM4E (0.54) HTTGAAKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116003710-B Polyacrylic polymer modified substrate, preparation method thereof and application thereof in preparation of biochip 中国海洋大学 2025-04-08 CN disclosed
CN-116003710-A Polyacrylic polymer modified substrate, preparation method thereof and application thereof in preparation of biochip 中国海洋大学 2023-04-25 CN disclosed
US-20210060121-A1 NOVEL ANTIBIOTICS AND METHODS OF USING THEM VERSITECH LIMITED (CN) 2021-03-04 US disclosed
CN-112204045-A Novel antibiotics and methods of use thereof 港大科桥有限公司 2021-01-08 CN disclosed
US-9150510-B2 Amino acid derivative NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2015-10-06 US disclosed
EP-2345635-A1 AMINO ACID DERIVATIVE Nippon Zoki Pharmaceutical Co., Ltd. (JP) 2011-07-20 EP disclosed
US-20110172442-A1 AMINO ACID DERIVATIVE NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2011-07-14 US disclosed
EP-1054004-B1 NOVEL PYRIMIDINE-5-CARBOXAMIDE DERIVATIVES ASTELLAS PHARMA INC (JP) 2008-07-16 EP disclosed
EP-1745058-A1 CYCLOOLEFIN PHOSPHINE LIGANDS AND THEIR USE IN CATALYSIS Degussa GmbH (DE) 2007-01-24 EP disclosed
US-7002020-B1 Oxazolidinone combinatorial libraries, compositions and methods of preparation PHARMACIA & UPJOHN COMPANY (US) 2006-02-21 US disclosed
US-20050004174-A1 Antibacterial agents GORDEEV MIKHAIL F (US) 2005-01-06 US disclosed
US-6562844-B2 Attaching an olefin to a solid support; oxidizing the olefin to provide an epoxide functionality; opening the epoxide with an amine to form an amino alcohol; cyclizing the amino alcohol using a phosgene equivalent PHARMACIA & UPJOHN COMPANY 2003-05-13 US disclosed
US-6531470-B1 Antimicrobial compounds PHARMACIA & UPJOHN COMPANY 2003-03-11 US disclosed
US-6432963-B1 ANTIINFLAMMATORY AGENTS; TYROSINE KINASE INHIBITOR YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2002-08-13 US disclosed
US-6239152-B1 Oxazolidinone combinatorial libraries, compositions and methods of preparation PHARMACIA & UPJOHN COMPANY 2001-05-29 US disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP disclosed
EP-1054004-A1 NOVEL PYRIMIDINE-5-CARBOXAMIDE DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2000-11-22 EP disclosed
EP-1049682-A1 OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION Versicor, Inc. (US) 2000-11-08 EP disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 WO disclosed
WO-1999037630-A1 OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION VERSICOR, INC. (US) 1999-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172442-A1 AMINO ACID DERIVATIVE OPRL1, OPRK1, SLC1A1 HTT 1158/4885GAA 3310/4885SMN1; SMN2 712/4885
US-20210060121-A1 NOVEL ANTIBIOTICS AND METHODS OF USING THEM VIP, TLR5, TREH HTT 1826/4885GAA 988/4885SMN1; SMN2 4742/4885
US-20050004174-A1 Antibacterial agents PAICS, OXA1L, PNKP HTT 4428/4885GAA 2871/4885SMN1; SMN2 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.